Bladder Cancer

Latest Bladder Cancer News

MRI-Based Assessment May Eliminate Need for TURBT in Muscle-Invasive Bladder Cancer

Publish Date September 15, 2022

MRI-based assessment shortened the time to correct treatment, when compared with TURBT, for patients with MIBC.

More Advanced Bladder Cancers Encountered After COVID-19 Pandemic

Publish Date September 2, 2022

Investigators hypothesize that patients presented later to their health care providers during the first year of the pandemic.

Tislelizumab Shows Promising Antitumor Benefits in Advanced Bladder Cancer

Publish Date September 1, 2022

In a small retrospective pilot study, the checkpoint inhibitor tislelizumab added to gemcitabine/cisplatin improved progression-free survival compared with gemcitabine/cisplatin alone among patients with locally advanced or metastatic bladder cancer.

Previous Cannabis Use Linked to Lower Risk of Some Genitourinary Cancers

Publish Date August 30, 2022

A new study suggests that previous use of cannabis is associated with a lower risk of certain genitourinary cancers.

Gemcitabine/Docetaxel Treats Nonmuscle-Invasive Bladder Cancer

Publish Date August 26, 2022

Authors say Gem/Doce warrants further study for the treatment of BCG-naive high-risk non-muscle-invasive bladder cancer

Optimal Duration of Neoadjuvant Gemcitabine + Cisplatin for MIBC Probed

Publish Date August 24, 2022

The neoadjuvant chemotherapy regimen may be especially effective against micrometastatic disease, investigators suggested.

Cancer Risk Higher for Men Versus Women at Most Shared Anatomic Sites

Publish Date August 18, 2022

The proportion of excess cancer risk in men that was explained by risk factors was modest, ranging from 50 to 11%

Opioid Use in Advanced Urothelial Carcinoma Quantified

Publish Date August 9, 2022

Pain requiring opioids is more common among patients with locally advanced or metastatic urothelial carcinoma compared with a matched control group of patients without cancer, a study found.

Risk Stratification Examined for High-Grade Ta Bladder Tumors

Publish Date August 5, 2022

For patients treated with adequate BCG, risk for BCG unresponsiveness, progression similar for all high-grade Ta tumors

Recurrent NMIBC Effectively Treated With Salvage Valrubicin+Docetaxel

Publish Date August 3, 2022

Investigators studied the effect of sequential valrubicin and docetaxel in patients with recurrent NMIBC following treatment with intravesical bacillus Calmette-Guérin and/or gemcitabine-docetaxel.